{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:41:11Z","timestamp":1790394071591,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejmech.2019.111588","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:41:48Z","timestamp":1565120508000},"page":"111588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5504","authenticated-orcid":false,"given":"Constantinos G.","family":"Neochoritis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Atmaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Twarda-Clapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Surmiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Skalniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Maria","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Muszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-313X","authenticated-orcid":false,"given":"Katarzyna","family":"Kurpiewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-1651","authenticated-orcid":false,"given":"Justyna","family":"Kalinowska-T\u0142u\u015bcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-6024","authenticated-orcid":false,"given":"Tad A.","family":"Holak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"D\u00f6mling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111588_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J.\u00a0Health Econ."},{"key":"10.1016\/j.ejmech.2019.111588_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/ol034077e","article-title":"Short and diverse route toward complex natural product-like macrocycles","volume":"5","author":"Beck","year":"2003","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.111588_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15406\/mojpb.2017.05.00157","article-title":"Intrinsically disordered proteins as drug targets","volume":"5","author":"Martinez","year":"2017","journal-title":"MOJ Proteomics Bioinforma"},{"key":"10.1016\/j.ejmech.2019.111588_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/17460441.2016.1107041","article-title":"Targeting intrinsically disordered proteins in rational drug discovery","volume":"11","author":"Ambadipudi","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111588_bib5","doi-asserted-by":"crossref","first-page":"22298","DOI":"10.1038\/srep22298","article-title":"Structure-based inhibitor design for the intrinsically disordered protein c-myc","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.111588_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087133","article-title":"Targeting the intrinsically disordered structural ensemble of \u03b1-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease","volume":"9","author":"T\u00f3th","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111588_bib7","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.jmb.2018.04.008","article-title":"Targeting intrinsically disordered transcription factors: changing the paradigm","volume":"430","author":"Tsafou","year":"2018","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbapap.2012.12.008","article-title":"Unusual biophysics of intrinsically disordered proteins","volume":"1834","author":"Uversky","year":"2013","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.ejmech.2019.111588_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pro.2261","article-title":"A\u00a0decade and a half of protein intrinsic disorder: biology still waits for physics","volume":"22","author":"Uversky","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tibs.2012.08.004","article-title":"Intrinsically disordered proteins: a 10-year recap","volume":"37","author":"Tompa","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111588_bib12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/sj.bjc.6602164","article-title":"Targeting the p53\u2013MDM2 interaction to treat cancer","volume":"91","author":"Klein","year":"2004","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2019.111588_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.111588_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"80-","key":"10.1016\/j.ejmech.2019.111588_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.274.5289.948","article-title":"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain","volume":"274","author":"Kussie","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.111588_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032839","article-title":"Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists","volume":"7","author":"Koes","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111588_bib17","doi-asserted-by":"crossref","first-page":"14801","DOI":"10.1073\/pnas.96.26.14801","article-title":"The alpha -helical FXXPhi Phi motif in p53: TAF interaction and discrimination by MDM2","volume":"96","author":"Uesugi","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib18","doi-asserted-by":"crossref","first-page":"29426","DOI":"10.1074\/jbc.M003107200","article-title":"Local structural elements in the mostly unstructured transcriptional activation domain of human p53","volume":"275","author":"Lee","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib19","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1021\/jm070095g","article-title":"Transient pockets on protein surfaces involved in Protein\u2212Protein interaction","volume":"50","author":"Eyrisch","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.4161\/cc.6.19.4740","article-title":"Molecular basis for the inhibition of p53 by mdmx","volume":"6","author":"Popowicz","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2019.111588_bib21","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.4161\/cc.6365","article-title":"Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain","volume":"7","author":"Popowicz","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2019.111588_bib22","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1471-2105-10-S15-S6","article-title":"Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100","volume":"10","author":"Dastidar","year":"2009","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejmech.2019.111588_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jmb.2005.05.010","article-title":"Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding","volume":"350","author":"Uhrinova","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib24","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1073\/pnas.0334477100","article-title":"Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation","volume":"100","author":"McCoy","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib25","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1021\/ja800201j","article-title":"Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft","volume":"130","author":"Showalter","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111588_bib26","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1021\/ja301255n","article-title":"Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser 17 phosphorylation in MDM2 reexamined","volume":"134","author":"Zhan","year":"2012","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111588_bib27","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.str.2015.10.016","article-title":"Exploiting transient protein states for the design of small-molecule stabilizers of mutant p53","volume":"23","author":"Joerger","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111588_bib28","doi-asserted-by":"crossref","first-page":"17059","DOI":"10.1021\/ja305839b","article-title":"Ordering of the N-terminus of human MDM2 by small molecule inhibitors","volume":"134","author":"Michelsen","year":"2012","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111588_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cbpa.2008.04.603","article-title":"Small molecular weight protein\u2013protein interaction antagonists\u2014an insurmountable challenge?","volume":"12","author":"D\u00f6mling","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib30","first-page":"1","article-title":"A\u00a0therapeutic patent overview of MDM2\/X-targeted therapies (2014\u20132018)","author":"Skalniak","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.111588_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/cmdc.201500487","article-title":"How to design a successful p53-MDM2\/X interaction inhibitor: a thorough overview based on crystal structures","volume":"11","author":"Estrada-Ortiz","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111588_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/acsmedchemlett.7b00219","article-title":"Artificial macrocycles as potent p53\u2013MDM2 inhibitors","volume":"8","author":"Estrada-Ortiz","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111588_bib33","first-page":"4107","article-title":"Mapping of the p53 and mdm-2 interaction domains","volume":"13","author":"Chen","year":"1993","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib34","first-page":"2523","article-title":"Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides","volume":"9","author":"Picksley","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2019.111588_bib35","first-page":"167","article-title":"p53\u2013MDM2 and MDMX Antagonists","author":"Neochoritis","year":"2014","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib36","first-page":"14774","article-title":"A\u00a0fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53 wt osteosarcoma cells","author":"Skalniak","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2019.111588_bib37","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.str.2013.09.006","article-title":"Transient protein states in designing inhibitors of the MDM2-p53 interaction","volume":"21","author":"Bista","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111588_bib38","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.str.2013.11.003","article-title":"Hitting a moving target: targeting transient protein states","volume":"21","author":"Bauer","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.111588_bib39","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1002\/anie.201001343","article-title":"Robust generation of Lead compounds for protein\u2013protein interactions by computational and MCR chemistry: p53\/hdm2 antagonists","volume":"49","author":"Czarna","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.111588_bib40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1021\/cb400728e","article-title":"Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities","volume":"9","author":"Huang","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ejmech.2016.11.029","article-title":"Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction","volume":"126","author":"Surmiak","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/acsmedchemlett.7b00219","article-title":"Artificial macrocycles as potent p53-MDM2 inhibitors","volume":"8","author":"Estrada-Ortiz","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111588_bib43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1039\/C7MD00058H","article-title":"Scaffold hopping via ANCHOR.QUERY: \u03b2-lactams as potent p53-MDM2 antagonists","volume":"8","author":"Shaabani","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2019.111588_bib44","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1016\/j.bmcl.2015.11.019","article-title":"2,3\u2032-Bis(1\u2032H-indole) heterocycles: new p53\/MDM2\/MDMX antagonists","volume":"25","author":"Neochoritis","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111588_bib45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pro.3303","article-title":"AnchorQuery: rapid online virtual screening for small-molecule protein-protein interaction inhibitors","volume":"27","author":"Koes","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib46","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4161\/cc.9.6.10956","article-title":"Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX\/MDM2 antagonist drug discovery","volume":"9","author":"Popowicz","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2019.111588_bib47","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/jm3012068","article-title":"Principles and applications of halogen bonding in medicinal chemistry and chemical biology","volume":"56","author":"Wilcken","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib48","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4161\/cc.8.8.8185","article-title":"High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx","volume":"8","author":"Czarna","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2019.111588_bib49","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A\u00a0medicinal chemist's guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib50","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2\u2212p53 interaction","volume":"49","author":"Ding","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib51","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.bmcl.2012.03.083","article-title":"The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction","volume":"22","author":"Furet","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111588_bib52","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1021\/jo902369g","article-title":"Cyclic guanidine organic catalysts: what is magic about triazabicyclodecene?","volume":"74","author":"Kiesewetter","year":"2009","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111588_bib53","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1021\/acs.orglett.5b00759","article-title":"Efficient isocyanide-less isocyanide-based multicomponent reactions","volume":"17","author":"Neochoritis","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.111588_bib54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1021\/acscombsci.5b00066","article-title":"Leuckart-wallach route toward isocyanides and some applications","volume":"17","author":"Neochoritis","year":"2015","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.ejmech.2019.111588_bib55","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/cr500043b","article-title":"NMR-based approaches for the identification and optimization of inhibitors of protein\u2013protein interactions","volume":"114","author":"Barile","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.111588_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pnmrs.2007.04.001","article-title":"NMR methods for the determination of protein\u2013ligand dissociation constants","volume":"51","author":"Fielding","year":"2007","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."},{"issue":"274","key":"10.1016\/j.ejmech.2019.111588_bib57","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","article-title":"Discovering high-affinity ligands for proteins: SAR by NMR","volume":"80","author":"Shuker","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.111588_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnmrs.2013.02.001","article-title":"Using chemical shift perturbation to characterise ligand binding","volume":"73","author":"Williamson","year":"2013","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."},{"key":"10.1016\/j.ejmech.2019.111588_bib59","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nsb1101-923","article-title":"The way to NMR structures of proteins","volume":"8","author":"W\u00fcthrich","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2019.111588_bib60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/bi000930v","article-title":"Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 \u2020","volume":"40","author":"Stoll","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111588_bib61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s000180050273","article-title":"Functions of the MDM2 oncoprotein","volume":"55","author":"Freedman","year":"1999","journal-title":"Cell. Mol. Life Sci. C."},{"key":"10.1016\/j.ejmech.2019.111588_bib62","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/0008-5472.CAN-16-2055","article-title":"p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy","volume":"76","author":"El-Deiry","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111588_bib63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF02192855","article-title":"Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions","volume":"2","author":"Piotto","year":"1992","journal-title":"J.\u00a0Biomol. NMR"},{"key":"10.1016\/j.ejmech.2019.111588_bib64","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/jmrb.1995.1109","article-title":"Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection Scheme that avoids water saturation","volume":"108","author":"Mori","year":"1995","journal-title":"J.\u00a0Magn. Reson., Ser. B"},{"key":"10.1016\/j.ejmech.2019.111588_bib65","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/bi000930v","article-title":"Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53","volume":"40","author":"Stoll","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111588_bib66","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1021\/acs.jmedchem.7b00104","article-title":"1,4,5-Trisubstituted imidazole-based p53\u2013MDM2\/MDMX antagonists with aliphatic linkers for conjugation with biological carriers","volume":"60","author":"Twarda-Clapa","year":"2017","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419307226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419307226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:58:10Z","timestamp":1759327090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419307226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":66,"alternative-id":["S0223523419307226"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111588","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111588"}}